RFX5
DNA-binding protein RFX5
Also known as: RFX5_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P48382
- Gene
- RFX5
- Ensembl
- ENSG00000143390
- Chromosome
- 1
- Canonical length
- 616 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Vesicles
- Quaternary structure
- Homodimer
OverviewNCBI Gene
A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
616 residues, UniProt reviewed canonical sequence.
>P48382|RFX5
1 MAEDEPDAKS PKTGGRAPPG GAEAGEPTTL LQRLRGTISK AVQNKVEGIL QDVQKFSDND
61 KLYLYLQLPS GPTTGDKSSE PSTLSNEEYM YAYRWIRNHL EEHTDTCLPK QSVYDAYRKY
121 CESLACCRPL STANFGKIIR EIFPDIKARR LGGRGQSKYC YSGIRRKTLV SMPPLPGLDL
181 KGSESPEMGP EVTPAPRDEL VEAACALTCD WAERILKRSF SSIVEVARFL LQQHLISARS
241 AHAHVLKAMG LAEEDEHAPR ERSSKPKNGL ENPEGGAHKK PERLAQPPKD LEARTGAGPL
301 ARGERKKSVV ESSAPGANNL QVNALVARLP LLLPRAPRSL IPPIPVSPPI LAPRLSSGAL
361 KVATLPLSSR AGAPPAAVPI INMILPTVPA LPGPGPGPGR APPGGLTQPR GTENREVGIG
421 GDQGPHDKGV KRTAEVPVSE ASGQAPPAKA AKQDIEDTAS DAKRKRGRPR KKSGGSGERN
481 STPLKSAAAM ESAQSSRLPW ETWGSGGEGN SAGGAERPGP MGEAEKGAVL AQGQGDGTVS
541 KGGRGPGSQH TKEAEDKIPL VPSKVSVIKG SRSQKEAFPL AKGEVDTAPQ GNKDLKEHVL
601 QSSLSQEHKD PKATPPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RFX5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.63
- Highest tissue expression
- 67 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 67 nTPM
- lymph node: 63 nTPM
- spleen: 48 nTPM
- thymus: 47 nTPM
- appendix: 41 nTPM
- duodenum: 30 nTPM
Single-cell type
- late spermatids: 30 nCPM
- late primary spermatocytes: 29 nCPM
- kupffer cells: 26 nCPM
- epididymal basal cells: 24 nCPM
- gastric progenitor cells: 23 nCPM
- epididymal clear cells: 23 nCPM
Immune cell
- naive B-cell: 54 nTPM
- memory B-cell: 48 nTPM
- myeloid DC: 47 nTPM
- NK-cell: 32 nTPM
- non-classical monocyte: 31 nTPM
- T-reg: 29 nTPM
Brain region
- pons: 34 nTPM
- cerebellum: 33 nTPM
- midbrain: 32 nTPM
- medulla oblongata: 31 nTPM
- hypothalamus: 31 nTPM
- thalamus: 29 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RFX5.
Disease | AllUniProt
Conditions RFX5 is implicated in, by any mechanism.
- MHC class II deficiency 3 (MHC2D3) MIM:620816
- MHC class II deficiency 5 (MHC2D5) MIM:620818
Disease | GeneticClinVar
51 pathogenic / likely-pathogenic of 475 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- MHC class II deficiency
- MHC class II deficiency 3
- MHC class II deficiency 5
- RFX5-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.1
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.48
- DepMap mean gene effect
- -0.25
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of transcription by RNA polymerase II
- positive regulation of MHC class II biosynthetic process
- positive regulation of transcription by RNA polymerase II
- regulation of transcription by RNA polymerase II
Molecular functions
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- transcription coregulator binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RFX5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RFX5 as an antibody target. Whether an autoantibody or antibody against RFX5 could matter depends on whether native RFX5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RFX5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RFX5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...